|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim K, Zang R, Choi SC, Ryu SY and Kim JW:
Current status of gynecological cancer in China. J Gynecol Oncol.
20:72–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Legge F, Ferrandina G, Salutari V and
Scambia G: Biological characterization of ovarian cancer:
prognostic and therapeutic implications. Ann Oncol. 16(Suppl 4):
iv95–101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seidman JD, Soslow RA, Vang R, Berman JJ,
Stoler MH, Sherman ME, Oliva E, Kajdacsy-Balla A, Berman DM and
Copeland LJ: Borderline ovarian tumors: Diverse contemporary
viewpoints on terminology and diagnostic criteria with illustrative
images. Hum Pathol. 35:918–933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. Int J Gynaecol Obstet. 95(Suppl 1):
S161–S192. 2006. View Article : Google Scholar
|
|
9
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Djuranovic S, Nahvi A and Green R: A
parsimonious model for gene regulation by miRNAs. Science.
331:550–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kasinski AL and Slack FJ: Epigenetics and
genetics MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng AM, Byrom MW, Shelton J and Ford LP:
Antisense inhibition of human miRNAs and indications for an
involvement of miRNA in cell growth and apoptosis. Nucleic Acids
Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Leva G and Croce CM: The role of
microRNAs in the tumori-genesis of ovarian cancer. Front Oncol.
3:1532013. View Article : Google Scholar
|
|
18
|
Dahiya N and Morin PJ: MicroRNAs in
ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010.
View Article : Google Scholar :
|
|
19
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X, et al: miR-141 and miR-200a act on ovarian
tumorigenesis by controlling oxidative stress response. Nat Med.
17:1627–1635. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dahiya N, Sherman-Baust CA, Wang TL,
Davidson B, Shih IeM, Zhang Y, Wood W III, Becker KG and Morin PJ:
MicroRNA expression and identification of putative miRNA targets in
ovarian cancer. PLoS One. 3:e24362008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu X, Macdonald DM, Huettner PC, Feng Z,
El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN and Wang X:
A miR-200 microRNA cluster as prognostic marker in advanced ovarian
cancer. Gynecol Oncol. 114:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng W, Liu T, Wan X, Gao Y and Wang H:
MicroRNA-199a targets CD44 to suppress the tumorigenicity and
multidrug resistance of ovarian cancer-initiating cells. FEBS J.
279:2047–2059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laios A, O'Toole S, Flavin R, Martin C,
Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al:
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Mol Cancer. 7:352008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagaraja AK, Creighton CJ, Yu Z, Zhu H,
Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM,
et al: A link between mir-100 and FRAP1/mTOR in clear cell ovarian
cancer. Mol Endocrinol. 24:447–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing
C and Liu Z: Altered expression of MiR-148a and MiR-152 in
gastrointestinal cancers and its clinical significance. J
Gastrointest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsuruta T, Kozaki K, Uesugi A, Furuta M,
Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a
tumor suppressor microRNA that is silenced by DNA hypermethylation
in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang J, Wang Y, Guo Y and Sun S:
Down-regulated microRNA-152 induces aberrant DNA methylation in
hepatitis B virus-related hepatocellular carcinoma by targeting DNA
methyltransferase 1. Hepatology. 52:60–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao
L, Cai H, Li P, Cao Q, Ju X, et al: miR-152 controls migration and
invasive potential by targeting TGFα in prostate cancer cell lines.
Prostate. 73:1082–1089. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou X, Zhao F, Wang Z-N, Song YX, Chang
H, Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a
in ovarian cancer is related to cell proliferation. Oncol Rep.
27:447–454. 2012.
|
|
31
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang L, Lai YK, Zhang J, Wang H, Lin MC,
He ML and Kung HF: Targeting S100P inhibits colon cancer growth and
metastasis by Lentivirus-mediated RNA interference and proteomic
analysis. Mol Med. 17:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Madhyastha HK, Radha KS, Nakajima Y, Omura
S and Maruyama M: uPA dependent and independent mechanisms of wound
healing by C-phycocyanin. J Cell Mol Med. 12:2691–2703. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Paris PL, Chen J, Ngo V, Yao H,
Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, et al: Next
generation sequencing of pancreatic cyst fluid microRNAs from low
grade-benign and high grade-invasive lesions. Cancer Lett.
356:404–409. 2015. View Article : Google Scholar
|
|
35
|
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu
G, Zhao R, Huang H, Wang X, Qiao Y, et al: MiR-152 and miR-185
co-contribute to ovarian cancer cells cisplatin sensitivity by
targeting DNMT1 directly: A novel epigenetic therapy independent of
decitabine. Oncogene. 33:378–386. 2014. View Article : Google Scholar
|
|
36
|
Zheng X, Chopp M, Lu Y, Buller B and Jiang
F: MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis
via NRP-2 and MMP-3. Cancer Lett. 329:146–154. 2013. View Article : Google Scholar :
|
|
37
|
Sharma SV and Settleman J: ErbBs in lung
cancer. Exp Cell Res. 315:557–571. 2009. View Article : Google Scholar
|
|
38
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi F, Telesco SE, Liu Y, Radhakrishnan R
and Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind
ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA.
107:7692–7697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ocana A, Vera-Badillo F, Seruga B,
Templeton A, Pandiella A and Amir E: HER3 overexpression and
survival in solid tumors: A meta-analysis. J Natl Cancer Inst.
105:266–273. 2013. View Article : Google Scholar
|
|
42
|
Cook RS, Garrett JT, Sánchez V, Stanford
JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger
L, et al: ErbB3 ablation impairs PI3K/Akt-dependent mammary
tumorigenesis. Cancer Res. 71:3941–3951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wimmer E, Kraehn-Senftleben G and Issing
WJ: HER3 expression in cutaneous tumors. Anticancer Res.
28:973–979. 2008.PubMed/NCBI
|
|
44
|
Reschke M, Mihic-Probst D, van der Horst
EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H and
Ullrich A: HER3 is a determinant for poor prognosis in melanoma.
Clin Cancer Res. 14:5188–5197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Prigent SA and Gullick WJ: Identification
of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and
SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831–2841.
1994.PubMed/NCBI
|
